• Something wrong with this record ?

Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry

DA. Hughes, G. Sunder-Plassmann, A. Jovanovic, E. Brand, ML. West, DG. Bichet, A. Pisani, A. Nowak, R. Torra, A. Khan, O. Azevedo, A. Lehman, A. Linhart, J. Rutecki, JD. Giuliano, E. Krusinska, P. Nordbeck

. 2025 ; 48 (1) : e12771. [pub] 20240719

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc25010530

Grant support
Amicus Therapeutics, Inc.
Takeda Pharmaceutical Company
Boston Scientific Corporation

Fabry disease is a progressive, X-linked lysosomal disorder caused by reduced or absent α-galactosidase A activity due to GLA variants. The effects of migalastat were examined in a cohort of 125 Fabry patients with migalastat-amenable GLA variants in the followME Pathfinders registry (EUPAS20599), an ongoing, prospective, patient-focused registry evaluating outcomes for current Fabry disease treatments. We report annualised estimated glomerular filtration rate (eGFR) and Fabry-associated clinical events (FACEs) in a cohort of patients who had received ≥3 years of migalastat treatment in a real-world setting. As of August 2022, 125 patients (60% male) had a mean migalastat exposure of 3.9 years. At enrolment, median age was 58 years (males, 57; females, 60) with a mean eGFR of 83.7 mL/min/1.73 m2 (n = 122; males, 83.7; females, 83.8) and a median left ventricular mass index of 115.1 g/m2 (n = 61; males, 131.2; females, 98.0). Mean (95% confidence interval) eGFR annualised rate of change in the overall cohort (n = 116) was -0.9 (-10.8, 9.9) mL/min/1.73 m2/year with a similar rate of change observed across patients with varying levels of kidney function at enrolment. Despite population age and baseline morbidity, 80% of patients did not experience a FACE during the mean 3.9 years of migalastat exposure. The incidence of renal, cardiac, and cerebrovascular events was 2.0, 83.2, and 4.1 events per 1000 patient-years, respectively. These data support a role of migalastat in preserving renal function and multisystem effectiveness during ≥3 years of migalastat treatment in this real-world Fabry population.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010530
003      
CZ-PrNML
005      
20250429134706.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12771 $2 doi
035    __
$a (PubMed)39031114
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hughes, Derralynn A $u Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK $1 https://orcid.org/0000000345319173
245    10
$a Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry / $c DA. Hughes, G. Sunder-Plassmann, A. Jovanovic, E. Brand, ML. West, DG. Bichet, A. Pisani, A. Nowak, R. Torra, A. Khan, O. Azevedo, A. Lehman, A. Linhart, J. Rutecki, JD. Giuliano, E. Krusinska, P. Nordbeck
520    9_
$a Fabry disease is a progressive, X-linked lysosomal disorder caused by reduced or absent α-galactosidase A activity due to GLA variants. The effects of migalastat were examined in a cohort of 125 Fabry patients with migalastat-amenable GLA variants in the followME Pathfinders registry (EUPAS20599), an ongoing, prospective, patient-focused registry evaluating outcomes for current Fabry disease treatments. We report annualised estimated glomerular filtration rate (eGFR) and Fabry-associated clinical events (FACEs) in a cohort of patients who had received ≥3 years of migalastat treatment in a real-world setting. As of August 2022, 125 patients (60% male) had a mean migalastat exposure of 3.9 years. At enrolment, median age was 58 years (males, 57; females, 60) with a mean eGFR of 83.7 mL/min/1.73 m2 (n = 122; males, 83.7; females, 83.8) and a median left ventricular mass index of 115.1 g/m2 (n = 61; males, 131.2; females, 98.0). Mean (95% confidence interval) eGFR annualised rate of change in the overall cohort (n = 116) was -0.9 (-10.8, 9.9) mL/min/1.73 m2/year with a similar rate of change observed across patients with varying levels of kidney function at enrolment. Despite population age and baseline morbidity, 80% of patients did not experience a FACE during the mean 3.9 years of migalastat exposure. The incidence of renal, cardiac, and cerebrovascular events was 2.0, 83.2, and 4.1 events per 1000 patient-years, respectively. These data support a role of migalastat in preserving renal function and multisystem effectiveness during ≥3 years of migalastat treatment in this real-world Fabry population.
650    _2
$a lidé $7 D006801
650    12
$a Fabryho nemoc $x farmakoterapie $7 D000795
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a registrace $7 D012042
650    12
$a 1-deoxynojirimycin $x analogy a deriváty $x terapeutické užití $7 D017485
650    12
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    12
$a alfa-galaktosidasa $x terapeutické užití $7 D000519
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ledviny $x patofyziologie $x účinky léků $7 D007668
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sunder-Plassmann, Gere $u Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
700    1_
$a Jovanovic, Ana $u Northern Care Alliance NHS Foundation Trust, Salford, UK
700    1_
$a Brand, Eva $u Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Interdisciplinary Fabry Center Münster, University Hospital Münster, Münster, Germany
700    1_
$a West, Michael L $u Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
700    1_
$a Bichet, Daniel G $u Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montréal, Quebec, Canada
700    1_
$a Pisani, Antonio $u Department of Public Health, Nephrology Unit, Federico II University Hospital, Naples, Italy
700    1_
$a Nowak, Albina $u Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland
700    1_
$a Torra, Roser $u Inherited Kidney Diseases, Nephrology Department, Fundació Puigvert, Institut d'Investigacions Biomèdiques (IIB-Snt Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
700    1_
$a Khan, Aneal $u M.A.G.I.C. (Metabolics and Genetics in Canada) Clinic Ltd., Calgary, Alberta, Canada
700    1_
$a Azevedo, Olga $u Cardiology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal
700    1_
$a Lehman, Anna $u Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Linhart, Aleš $u Second Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Rutecki, Jasmine $u Amicus Therapeutics, Inc., Princeton, New Jersey, USA
700    1_
$a Giuliano, Joseph D $u Amicus Therapeutics, Inc., Princeton, New Jersey, USA
700    1_
$a Krusinska, Eva $u Amicus Therapeutics, Inc., Princeton, New Jersey, USA
700    1_
$a Nordbeck, Peter $u University Hospital Würzburg, Würzburg, Germany
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 48, č. 1 (2025), s. e12771
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39031114 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134702 $b ABA008
999    __
$a ok $b bmc $g 2311727 $s 1247611
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 48 $c 1 $d e12771 $e 20240719 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
GRA    __
$p Amicus Therapeutics, Inc.
GRA    __
$p Takeda Pharmaceutical Company
GRA    __
$p Boston Scientific Corporation
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options